STOCK TITAN

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences clinical trial

BriaCell Therapeutics (Nasdaq: BCTX) has announced its upcoming presentation of three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30.

The presentations include: 1) Results from Bria-ABC1 versus physician choice in late-stage MBC with biomarker correlates from the randomized registration trial; 2) Survival outcomes from a randomized phase 2 trial of Bria-IMT, an allogeneic whole cell cancer vaccine; and 3) Findings on Bria-OTS+, described as a versatile therapeutic platform for inducing anti-cancer immunity.

The posters will be presented across different sessions focusing on clinical research, Phase II/III trials, and immunology. Following the presentations, the posters will be made available on BriaCell's website.

BriaCell Therapeutics (Nasdaq: BCTX) ha annunciato la sua prossima presentazione di tre poster al 2025 American Association for Cancer Research (AACR) Annual Meeting a Chicago dal 25 al 30 aprile.

Le presentazioni includono: 1) Risultati da Bria-ABC1 rispetto alla scelta del medico in MBC avanzato con correlati biomarker dallo studio randomizzato di registrazione; 2) Risultati di sopravvivenza da uno studio di fase 2 randomizzato di Bria-IMT, un vaccino contro il cancro a cellule intere allogenico; e 3) Risultati su Bria-OTS+, descritto come una piattaforma terapeutica versatile per indurre immunità anti-cancro.

I poster saranno presentati in diverse sessioni incentrate sulla ricerca clinica, studi di fase II/III e immunologia. Dopo le presentazioni, i poster saranno resi disponibili sul sito web di BriaCell.

BriaCell Therapeutics (Nasdaq: BCTX) ha anunciado su próxima presentación de tres carteles en el 2025 American Association for Cancer Research (AACR) Annual Meeting en Chicago del 25 al 30 de abril.

Las presentaciones incluyen: 1) Resultados de Bria-ABC1 frente a la elección del médico en MBC en etapa avanzada con correlatos biomarcadores del ensayo de registro aleatorizado; 2) Resultados de supervivencia de un ensayo de fase 2 aleatorizado de Bria-IMT, una vacuna contra el cáncer de células completas alogénica; y 3) Hallazgos sobre Bria-OTS+, descrito como una plataforma terapéutica versátil para inducir inmunidad contra el cáncer.

Los carteles se presentarán en diferentes sesiones centradas en la investigación clínica, ensayos de fase II/III e inmunología. Después de las presentaciones, los carteles estarán disponibles en el sitio web de BriaCell.

BriaCell Therapeutics (Nasdaq: BCTX)는 2025년 미국 암 연구 협회(AACR) 연례 회의에서 4월 25일부터 30일까지 시카고에서 세 개의 포스터를 발표할 예정이라고 발표했습니다.

발표 내용은 다음과 같습니다: 1) 무작위 등록 시험에서 바이오마커 상관관계를 가진 말기 MBC에서 Bria-ABC1과 의사 선택의 결과; 2) 동종 전체 세포 암 백신인 Bria-IMT의 무작위 2상 시험에서의 생존 결과; 3) 항암 면역 유도를 위한 다목적 치료 플랫폼으로 설명된 Bria-OTS+에 대한 발견.

포스터는 임상 연구, 2/3상 시험 및 면역학에 중점을 둔 다양한 세션에서 발표될 예정입니다. 발표 후 포스터는 BriaCell 웹사이트에서 확인할 수 있습니다.

BriaCell Therapeutics (Nasdaq: BCTX) a annoncé sa prochaine présentation de trois posters lors de la 2025 American Association for Cancer Research (AACR) Annual Meeting à Chicago du 25 au 30 avril.

Les présentations incluent : 1) Résultats de Bria-ABC1 par rapport au choix du médecin dans le cas du MBC avancé avec des corrélations de biomarqueurs provenant de l'essai d'enregistrement randomisé ; 2) Résultats de survie d'un essai de phase 2 randomisé de Bria-IMT, un vaccin contre le cancer à cellules entières allogénique ; et 3) Découvertes sur Bria-OTS+, décrit comme une plateforme thérapeutique polyvalente pour induire une immunité anti-cancer.

Les posters seront présentés lors de différentes sessions axées sur la recherche clinique, les essais de phase II/III et l'immunologie. Après les présentations, les posters seront disponibles sur le site Web de BriaCell.

BriaCell Therapeutics (Nasdaq: BCTX) hat die bevorstehende Präsentation von drei Postern auf dem 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago vom 25. bis 30. April angekündigt.

Die Präsentationen umfassen: 1) Ergebnisse von Bria-ABC1 im Vergleich zur Wahl des Arztes bei fortgeschrittenem MBC mit Biomarker-Korrelaten aus der randomisierten Registrierungstudie; 2) Überlebensdaten aus einer randomisierten Phase-2-Studie von Bria-IMT, einem allogenen Ganzzellen-Impfstoff gegen Krebs; und 3) Erkenntnisse zu Bria-OTS+, beschrieben als eine vielseitige therapeutische Plattform zur Induktion von Anti-Krebs-Immunität.

Die Poster werden in verschiedenen Sitzungen präsentiert, die sich auf klinische Forschung, Phase-II/III-Studien und Immunologie konzentrieren. Nach den Präsentationen werden die Poster auf der Website von BriaCell verfügbar sein.

Positive
  • Company advancing multiple clinical programs simultaneously (Bria-ABC1, Bria-IMT, Bria-OTS+)
  • Reaching late-stage clinical development with registration trial for Bria-ABC1
  • Progress in Phase 2 trials with survival outcome data available for presentation
Negative
  • None.

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company will be presenting three posters at the 2025 American Association for Cancer Research (AACR) Annual Meeting taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The details are listed below. The abstracts will be published in the online Proceedings of the AACR.

Poster 1:
Title: Bria-ABC1 vs physician choice in late-stage MBC; early biomarker correlates of the randomized registration trial
Session Title: Late-Breaking Research: Clinical Research 4
Session Date and Time: 4/30/2025 9:00 AM – 12:00 PM CST
Location: Poster Section 49
Poster Board Number: 14
Abstract Presentation Number: LB408

Poster 2:
Title: Survival outcomes in a randomized phase 2 of Bria-IMT: An allogeneic whole cell cancer vaccine
Session Title: Phase II and Phase III Clinical Trials
Session Start: 4/28/2025 2:00 PM – 5:00 PM CST
Location: Poster Section 50
Poster Board Number: 18
Abstract Presentation Number: CT100

Poster 3:
Title: Bria-OTS+: A versatile therapeutic platform for inducing anti-cancer immunity
Session Category: Immunology
Session Title: Vaccines, In Situ Vaccines, and Vaccine Combinations
Session Date and Time: 4/28/2025 2:00 – 5:00 PM CST
Location: Poster Section 39
Poster Board Number: 29
Published Abstract Number: 3553

Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about presenting three posters at the 2025 AACR, and the contents of such posters, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com 

Investor Relations Contact:
investors@briacell.com


1 Bria-ABC refers to the pivotal Phase 3 Study entitled, Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer (BRIA-ABC) NCT06072612


FAQ

What clinical trials will BCTX present at AACR 2025?

BCTX will present data from Bria-ABC1 registration trial in late-stage MBC, Phase 2 trial results of Bria-IMT cancer vaccine, and research on Bria-OTS+ therapeutic platform.

When and where will BriaCell (BCTX) present at AACR 2025?

BriaCell will present at the AACR Annual Meeting from April 25-30, 2025, at McCormick Place Convention Center in Chicago.

What are the presentation topics for BCTX's Bria-ABC1 trial?

The Bria-ABC1 presentation will cover biomarker correlates from the randomized registration trial comparing the treatment to physician choice in late-stage MBC.

What type of data will BCTX present about Bria-IMT?

BCTX will present survival outcomes data from a randomized Phase 2 trial of Bria-IMT, their allogeneic whole cell cancer vaccine.
Briacell Therapeutics Corp

NASDAQ:BCTX

BCTX Rankings

BCTX Latest News

BCTX Stock Data

12.99M
3.46M
12.96%
14.05%
4.96%
Biotechnology
Pharmaceutical Preparations
Link
Canada
WEST VANCOUVER